✦ LIBER ✦

P-2-88 Comparison of fluvoxamine and fluoxetine in major depression

✍ Scribed by M. Rapaport; E. Coccaro; Y. Sheline; P. Holland; T. Perse; L. Fabre

Book ID: 119176159
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 140 KB
Volume: 5
Category: Article
ISSN: 0924-977X
DOI: 10.1016/0924-977x(95)90453-k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fluvoxamine versus fluoxetine in major d

Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison

✍ Jean Dalery; Adriaan Honig 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract A double‐blind, multinational study was conducted to compare the efficacy and safety of fluvoxamine and fluoxetine in outpatients with major depressive episode; 184 patients were randomised to fluvoxamine (100 mg/day) or fluoxetine (20 mg/day) for 6 weeks. Both drugs were effective and

Controlled comparison of paroxetine and

Controlled comparison of paroxetine and fluvoxamine in major depression

✍ M. Ansseau; A. Gabriëls; J. Loyens; F. Bartholomé; J. L. Evrard; A. De Nayer; R. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB

A multicentre study compared the antidepressant efficacy and the tolerance of two selective serotonin reuptake inhibitors, paroxetine (20-30 mg/d) and fluvoxamine (50-200 mg/d) in two parallel groups of respectively 56 and 64 patients with major depression, as defined by DSM-III-R criteria. The dura

Controlled comparison of milnacipran and

Controlled comparison of milnacipran and fluoxetine in major depression

✍ Marc Ansseau; Patrick Papart; Benoît Troisfontaines; Franz Bartholomé; Michel Ba 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 686 KB

A double-blind comparison of paroxetine

A double-blind comparison of paroxetine and fluvoxamine in major depression

✍ Ansseau, M.; Gabriëls, A.; Loyens, J.; Bartholomé, F.; Evrard, J.; De Nayer, A.; 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 148 KB

P-2-35 Efficacy of fluoxetine in compari

P-2-35 Efficacy of fluoxetine in comparison to maprotiline and amitriptyline in major depression with anxious features

✍ D. Bugarski-Kirola; S. Totic; A. Damjanovic; Dj. Zivkovic 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Comparison of pramipexole, fluoxetine, a

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

✍ Mark H. Corrigan; Angelita Q. Denahan; C. Eugene Wright; Rhonda J. Ragual; Dwigh 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB 👁 2 views

Pramipexole, a dopamine D 2 receptor agonist, was tested in 174 patients with major depression, with or without melancholia and without psychotic features. Three daily dose levels (0.375 mg, 1.0 mg, and 5.0 mg) were compared to fluoxetine (Prozac) at 20 mg and placebo in a randomized, double-blind,